Efficacy and safety of pemetrexed in elderly cancer patients: Results of an integrated analysis

Critical Reviews in Oncology/Hematology

Volumn 67, Issue 1, 2008, Pages 64-70

  Kulkarni, Pandurang M ^a   Chen, Ruqin ^a   Anand, Taruna ^b   Monberg, Matthew J ^a   Obasaju, Coleman K ^a  

^a ELI LILLY AND COMPANY   (United States)

^b TATA CONSULTANCY SERVICES   (India)

Author keywords

Chemotherapy; Elderly; Integrated study; Mesothelioma; Metastatic cancer; Non small cell lung cancer; Pancreatic cancer; Pemetrexed; Pooled study

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; FOLIC ACID; GEMCITABINE; PEMETREXED;

ADULT; AGED; ANEMIA; ANOREXIA; BONE MARROW SUPPRESSION; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DERMATITIS; DESQUAMATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS CANCER; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PLEURA MESOTHELIOMA; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; GLUTAMATES; GUANINE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 44649133200     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.01.011     Document Type: Review

References (38)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics. CA Cancer J Clin 57 1 (2007) 43-66
2. Edwards B.K., Howe H.L., Ries L.A., Thun M.J., Rosenberg H.M., Yancik R., et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94 10 (2002) 2766-2792
3. SEER cancer statistics review, 1975-2004. Bethesda, MD: National Cancer Institute; 2007 (accessed at http://seer.cancer.gov/csr/1975_2004).
4. Ignoffo R. Cancer in the elderly: focus on pharmacotherapy. US Pharm 26 (2001) HS26-HS35
5. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 80 7 (1997) 1273-1283
6. Misra D., Seo P.H., and Cohen H.J. Aging and cancer. Clin Adv Hematol Oncol 2 7 (2004) 457-465
7. Wildiers H., Highley M.S., de Bruijn E.A., and van Oosterom A.T. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 42 14 (2003) 1213-1242
8. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 1 4 Suppl 2 (2003) 18-24
9. Kut V., Patel J.D., and Argiris A. Pemetrexed: a novel antifolate agent enters clinical practice. Expert Rev Anticancer Ther 4 4 (2004) 511-522
10. Calvert A.H. Biochemical pharmacology of pemetrexed. Oncology (Williston Park) 18 13 Suppl 8 (2004) 13-17
11. Hazarika M., White Jr. R.M., Booth B.P., Wang Y.C., Ham D.Y., Liang C.Y., et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 11 3 (2005) 982-992
12. Puto K., and Garey J.S. Pemetrexed therapy for malignant pleural mesothelioma. Ann Pharmacother 39 4 (2005) 678-683
13. De Marinis F., and De Petris L. Pemetrexed in second-line treatment of non-small-cell lung cancer. Oncology (Williston Park) 18 13 Suppl 8 (2004) 38-42
14. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 9 (2004) 1589-1597
15. Oettle H., Richards D., Ramanathan R.K., van Laethem J.L., Peeters M., Fuchs M., et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16 10 (2005) 1639-1645
16. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 14 (2003) 2636-2644
17. Pocock S.J., and Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31 1 (1975) 103-115
18. Vercelli M., Quaglia A., Casella C., Mangone L., and ITACARE Working Group. Cancer patient survival in the elderly in Italy. Tumori 83 1 (1997) 490-496
19. Wasil T., and Lichtman S.M. Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. Oncologist 10 8 (2005) 602-612
20. Rocha Lima C.M., Herndon J.E., Kosty M., Clamon G., and Green M.R. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 94 1 (2002) 181-187
21. Schild S.E., Stella P.J., Geyer S.M., Bonner J.A., McGinnis W.L., Mailliard J.A., et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 21 17 (2003) 3201-3206
22. Sequist L.V., and Lynch T.J. Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes!. J Clin Oncol 21 17 (2003) 3186-3188
23. Feliu J., et al., Oncopaz Cooperative Group. Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Cancer 86 8 (1999) 1463-1469
24. Kubota K., Furuse K., Kawahara M., Kodama N., Ogawara M., Takada M., et al. Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 40 6 (1997) 469-474
25. Rinaldi M., de Marinis F., and Ardizzoni A. Correlation between age and prognosis in patients with advanced non-small-cell lung cancer prognosis with cisplatin containing chemotherapy: a retrospective multicenter study. Ann Oncol 5 Suppl 8 (1994) 58
26. Langer C.J., Manola J., Bernardo P., Kugler J.W., Bonomi P., Cella D., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94 3 (2002) 173-181
27. Lilenbaum R.C., Herndon J.E., List M.A., Desch C., Watson D.M., Miller A.A., et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 23 1 (2005) 190-196
28. Langer C.J., Vangel M., and Schiller J. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 years) with NSCLC do as well as younger pts (<70). Chicago, IL, May 31-June 3 (2003), American Society of Clinical Oncology
29. Perrone F., Gallo C., and Gridelli C. Re: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94 13 (2002) 1029-1030, author reply 30-31
30. Hanauske A.R., Chen V., Paoletti P., and Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6 4 (2001) 363-373
31. Niyikiza C., Baker S.D., Seitz D.E., Walling J.M., Nelson K., Rusthoven J.J., et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1 7 (2002) 545-552
32. Bonadonna G., and Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304 1 (1981) 10-15
33. Chrischilles E.A., Link B.K., Scott S.D., Delgado D.J., and Fridman M. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma. Cancer Control 10 5 (2003) 396-403
34. Lyman G.H., Dale D.C., and Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21 24 (2003) 4524-4531
35. Dixon D.O., Neilan B., Jones S.E., Lipschitz D.A., Miller T.P., Grozea P.N., et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 4 3 (1986) 295-305
36. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 2 (2002) 92-98
37. Hensing T.A., Peterman A.H., Schell M.J., Lee J.H., and Socinski M.A. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced: stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 98 4 (2003) 779-788
38. Goodwin J.S., Samet J.M., and Hunt W.C. Determinants of survival in older cancer patients. J Natl Cancer Inst 88 15 (1996) 1031-1038